In this study, we investigated the incidence and prognostic impact of monosomal karyotype (MK) in 405 higher-risk Myelodysplastic Syndromes (MDS) patients treated with 5-AZA. The MK was present in 66 out of 405 (16.3%) patients, most of whom had complex karyotype (CK). MK was strongly associated with CK and the cytogenetic risk defined according to IPSS-R, as well as with high-risk disease, according to IPSS (P 5 .029), IPSS-R (P < .001), and WPSS (P < .001) classification systems. The overall response rate (ORR) was not different between MK1 and MK-patients (46.6% vs. 46.2%). At 28 months median follow-up, the median duration of response was 11 months in the entire cohort, 9.5 months in MK1 patients and 11 months in MK-patients (P 5 .024). The estimated median time to transformation to acute myeloid leukemia for MK1 patients was 17 months vs. 23 months for MK-patients (P 5 .025). The estimated median OS for MK1 patients was 12 months vs. 18 months for MK-patients (P < .001). Multivariate Cox regression analysis revealed that performance status (P < .001), IPSS-R (P < .001), and MK (P 5 .002) were independently associated with overall survival (OS). In a subgroup consisting of high and very-high risk patients according to IPSS-R, MK-patients showed better OS rates compared to MK1 patients (estimated median OS: 17 months vs. 12 months, P 5 .002). In conclusion, we found that MK is associated with reduced OS in patients with higher-risk MDS treated with 5-AZA. Furthermore, we showed that in MDS with high or very-high IPSS-R risk score, MK can further distinguish patients with worse outcome. 
| I N TR ODU C TI ON
Myelodysplastic Syndromes (MDS) are a heterogeneous group of clonal disorders characterized by bone marrow (BM) dysplasia, ineffective hematopoiesis and increased risk of transformation to acute myeloid leukemia (AML). 1 For prognostic purposes, the International Prognostic Scoring System (IPSS), which is based on the number of cytopenias, the percentages of BM blasts (including AML with 20%-30% blasts), and cytogenetics was applied to separate patients into four groups (low, In patients with AML, a separate cytogenetic group termed monosomal karyotype (MK), defined by the presence of 2 autosomal monosomies or one autosomal monosomy plus at least one structural abnormality in the same clone has been introduced and has been associated with worse outcomes. 4 In MDS, according to IPSS-R cytogenetic groups, patients with MK are included in the "poor" and "very poor" cytogenetic groups mainly due to its overlap with the complex karyotype (CK). During the last years, several data have arisen about the role of MK in the prognosis of MDS patients. The results, however, are conflicting. For instance, Gangat et al. showed the additional prognostic value of considering MK as a separate prognostic category within the group of "poor" and "very poor" cytogenetic categories according to the IPPS-R in a large cohort of untreated primary MDS patients. 4 However, others have suggested that the prognosis was related more to the presence of CK rather than MK. Treatment with 5-AZA prolongs time to transformation to AML and OS of higher-risk MDS patients. 6, 7 However, predictive factors of response and outcome after treatment with 5-AZA are largely unknown. Additionally, the results of published studies on the effect of MK in the outcomes of higher-risk MDS patients treated with AZA remain controversial. [8] [9] [10] The aim of this retrospective study of the Hellenic MDS Study Group was to investigate the incidence and prognostic impact of MK in higher-risk MDS patients treated with 5-AZA. /L, hemoglobin 11 g/dL, and no PB blasts were required. PR required that all criteria for CR be met, except BM blasts decreased by 50% over pretreatment levels but still >5%. Stable disease (SD) was defined as failure to achieve at least PR and no evidence of progression for >8 weeks. Patients not achieving at least PR were further assessed for HI by using the IWG criteria for MDS. HI was 
| Biostatistical analysis
To examine the potential prognostic value of MK with regard to transformation to AML and OS of higher-risk MDS patients, we performed
Kaplan-Meier survival analysis. The observed differences between Kaplan-Meier survival curves were evaluated by the log-rank (MantelCox) test. Moreover, we performed univariate Cox regression analysis, to assess potential associations between MK (or other established prognostic factors) and the risk for transformation of higher-risk MDS to AML as well as for death of higher-risk MSD patients. Furthermore, we built multivariate proportional hazard regression models, adjusted for MK, performance status (PS), and IPSS-R risk at treatment onset. The level of statistical significance was set at a probability value of less than 0.050 (P < .050).
| RE S U L TS

| Characteristics of the study population
Baseline patient characteristics are presented in Table 1 . The median age of the patients was 74 years (range: 33-89). There were 274 male 
| Associations of MK with established prognostic factors
The MK was present in 66 out of 405 (16.3%) patients, while CK was present in 74 out of 405 (18.3%) of patients. MK was strongly associated with CK and the cytogenetic risk defined according to IPSS-R, as well as with high-risk disease, according to IPSS (P 5 .029), IPSS-R (P < .001), and WPSS (P < .001) classification systems (Supporting Information Table S1 ).
| Response rates
The overall response rate (ORR) in the entire cohort was 46. Table S2 ).
Univariate Cox regression analysis revealed that MK, PS, and IPSS-R risk were significant prognostic factors for transformation to AML of higher-risk MDS patients [MK1 compared to MK-category: hazard ratio (HR)51.62, 95% CI 51.05-2.50, P 5 .029], whereas patient gender and age did not hold any prognostic significance (Table 2) . However, multivariate Cox regression analysis including MK, PS, and IPSS-R at the onset of treatment revealed that the presence of MK (MK1) is not an independent prognosticator of transformation to AML (HR 5 1.68, 95% CI 5 0.97-2.90, P 5 .062) ( Table 2 ).
| The independent prognostic significance of MK for MDS patients' OS
The estimated median OS time for MK1 patients was 12 months (95% CI 5 7.8-16.2) vs. 18 months (95% CI 5 15.3-20.7) for MK-patients (P < .001) (Figure 2A ). Furthermore, CK1 was a significant unfavorable prognosticator of patients' OS (P < .001). In this subgroup of MDS patients with poor prognostic outcome, the presence of MK did not hold any additional prognostic value (P 5 .79) (Supporting Information Figure 1b ). In addition, CK had a stronger unfavorable effect for the prognosis of MDS patients' OS compared to MK, as shown by multivariate Cox regression models including both CK and MK (Supporting Information Table S2 ). Univariate Cox regression analysis revealed that MK, PS, and IPSS-R risk were significant prognostic factors for OS of higher-risk MDS patients (MK1 compared to MK-category: HR 5 1.84, 95%
CI 5 1.34-2.51, P < .001), whereas patient gender and age did not hold any prognostic significance (Table 2) . Multivariate Cox regression analysis including MK, PS, and IPSS-R at the onset of treatment revealed that the presence of MK (MK1) is an independent predictor of poor OS (HR 5 1.86, 95% CI 5 1.26-2.76, P 5 .002) ( Table 2) . Moreover, in a subgroup consisting of high and very-high risk patients according to IPSS-R, MK-patients had better OS rates that MK1 patients (estimated median OS: 17 months; 95% CI 5 14.1-19.9 vs. 12 months, 95% CI 5 6.6-17.4, P 5 .002) ( Figure 2B ).
| D ISC USSION
Almost 50% of MDS patients have cytogenetic abnormalities and CK is a known negative prognostic factor. MK has been associated with poor 16 Xing et al.
found that MK1 patients have poor prognosis compared to MKpatients especially in the high-risk groups according to WPSS and IPSS-R. 17 However, in both of these studies patients were not treated with 5-AZA homogeneously. In accordance with our study, Cluzeau et al.
also supported the negative prognostic impact of MK on survival of MDS patients treated with 5-AZA. Furthermore, the same study classified the patients into three groups according to MK status and identified a very high-risk group with MK and poor OS. 9 Although the above data along with our study support the prog- The negative predictive value of MK in patients treated with AZA may be related to the presence of TP53 mutations. TP53 mutations are found in 82% of MDS patients with MK, and potentiate the possibility of mutation induced genetic/chromosome instability as the cause of this particular cytogenetic abnormality. 18 Takahashi et al. investigated the presence of TP53 mutations in 168 MDS patients who were treated with hypomethylating agents (HMA) and demonstrated the strong predictive and prognostic value of TP53 mutation status in these patients. 19 Others, however, question the independent prognostic value of TP53 mutations and recently Gangat et al. showed that the prognostic contribution of TP53 mutations was overridden by its association with MK. 20 In conclusion, our study supports that MK is associated with inferior OS in patients with higher-risk MDS treated with 5-AZA. In MDS with high or very high IPSS-R risk, MK can further distinguish patients with worse outcome. However, the data on this subject are still conflicting and further investigation is needed to clarify the prognostic role of MK.
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